an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction[J]. Cancer Research, 2023, 83(7_Supplement): 3449-3449. McePdfHeight Caution: Product has not been fully validated for medical applications. For research use only. Tel...
This indicates that the interaction of MRTFB and TEAD on a transcriptional level, perturbed by EWS-FLI1, is a network hub for the regulation of cytoskeletal processes such as migration and adhesion in EwS. DISCUSSION Early metastasis onset is still the major clinical challenge in the treatment ...
"Observing clinical activity in multiple patients who have exhausted all other treatment options strengthens our optimism about the potential of MRT-2359 for patients with MYC-driven solid tumors. This represents a sizable patient group, encompassing many cancer types, that current...
MRT-2359是具有抗肿瘤活性的GSPT1的口服活性和强效降解剂。MRT-2359还抑制耐药非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)细胞的生长。MRT-2359在MYC驱动的细胞系中表现出优先活性,如N-和L-MYC高NSCLC和SCLC患者来源的异种移植物(PDX)[1]。 MRT-2359名称 ...